Orchid Pharma Limited · NSE:ORCHPHARMA
Orchid Pharma — Q1 FY2025-26 Earnings Presentation
9 slides from Orchid Pharma's earnings presentation, Aug 12, 2025
Slide 1: Investor Presentation Q1 FY2025-26 filing letter to NSE and BSE
August 12, 2025 National Stock Exchange of India Limited, BSE Limited Exchange Plaza, Bandra Kurla Complex Phiroze Jeejeebhoy Towers, Bandra (E), Mumbai-400051 Dalal Street, Fort, Mumbai-400001 Symbol: ORCHPHARMA Scrip Code: 524372 Ref: (i) Regulation 30 of Securities and Exchange Board of India (Li
Slide 2: Financials Q1 & FY-26
Orchid Pharma Limited Financials Q1 & FY-26 • All results in Standalone basis. • These are approx. for exact nos. pls refer financials for details.
Slide 3: Financial Highlights Q1-26 FY-25
Financial Highlights Q1-26 FY-25 -29% +13% -27% +11% -38% +15% -38% +12%
Slide 4: Financial Performance
Financial Performance (Amt. in Cr.) Q1-26 Q1-25 Change % FY-25 FY-24 % Change Sales 173 244 -29% 922 819 +13% Other Income 16 8 +100% 32 30 +7% COGS 99 150 -34% 544 484 +12% Employee Exp 22 21 +5% 86 70 +23% Other Exp 38 40 -5% 168 155 +8% EBITDA* 30 41 -27% 156 140 +11% % to Sales 17% 17% 17% 17% I
Slide 5: Turnover (Amt. in Cr.)
Turnover (Amt. in Cr.) 300 244 250 200 183 173 150 131 96 100 50 - Q1-22 Q1-23 Q1-24 Q1-25 Q1-26
Slide 6: EBITDA, PBT & PAT as % to Sales Qtr-1 FY-26
EBIDTA, PBT & PAT as % to Sales Qtr-1 FY-26 20% 17% 17% 15% 12% 13% 12% 12% 10% 10% 10% 8% 6% 6% 5% 0% -5% -11% -11% -10% -15% -20% -25% -25% -25% -30% Q1-22 Q1-23 Q1-24 Q1-25 Q1-26 EBITDA 8% 12% 13% 17% 17% PBT -25% -11% 6% 12% 10% PAT -25% -11% 6% 12% 10% EBITDA PBT PAT
Slide 7: P&L Analysis – Gross Margin
P&L Analysis – Gross Margin % to Sales Gross Margin Quarterly Basis 60% 50% 50% 47% 43% 39% 39% 40% 30% 20% 10% 0% Q1-22 Q1-23 Q1-24 Q1-25 Q1-26
Slide 8: P&L Analysis – Exp. Q1-FY26
P&L Analysis – Exp. % to Sales Q1-FY26 35% 30% 30% 26% 25% 22% 20% 18% 15% 16% 15% 13% 11% 10% 9% 9% 5% 0% Q1-22 Q1-23 Q1-24 Q1-25 Q1-26 Emp Benefit Other Exp
Slide 9: Thank You
Thank You